IGF2 and cancer: Malignant transformation and metastasis formation have been reported to be promoted by growth-hormone-stimulated insulin-like growth factor I (IGF-I) in different malignancies [42,43,44], and antagonists of GHRH have been shown to suppress the tumoral production of IGF-I and IGF-II by inhibiting the secretion of GH and blocking the binding of autocrine GHRH to receptors on cancer cells [45,46,47].